Squarepoint’s Co-Diagnostics CODX Stock Holding History

Squarepoint’s Portfolio CODX Stock Details CODX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-840	Closed	-$18.9K	–	4695
2024 Q4	$18.9K	Buy	+840	New	+$26.5K	﹤0.01%	4938

Other funds holding CODX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PAG

Private Advisory Group Redmond, Washington $1.52B AUM 41.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

KAS

Kestra Advisory Services Austin, Texas $26.4B AUM 21.05% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Squarepoint's CODX Position: Q2 2025 in Review

Squarepoint sold out of Co-Diagnostics (CODX) in Q2 2025, closing a stake of 2,193 shares — an estimated $20.4K sold.

Squarepoint first reported a position in CODX in Q4 2020 and held it in 5 quarters. The position peaked at $231K in Q4 2020. 35 funds tracked by Wall St. Rank hold CODX as of Q2 2025.

Squarepoint reported no remaining Co-Diagnostics position as of Q2 2025 after selling out during the quarter.
Squarepoint sold 2,193 Co-Diagnostics shares in Q2 2025, an estimated $20.4K.
Squarepoint first reported a position in Co-Diagnostics in Q4 2020 and held it in 5 quarters.
Squarepoint's Co-Diagnostics position peaked at $231K in Q4 2020.
35 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2025.

Based on Squarepoint's 13F filing for Q2 2025, filed 14 Aug 2025.